<DOC>
	<DOCNO>NCT00839332</DOCNO>
	<brief_summary>The purpose Phase 1 portion study determine safe dose LY2603618 give 24 hour gemcitabine . This dose use Phase 2 portion study . The Phase 2 portion study evaluate whether LY2603618 administer 24 hour gemcitabine therapy effective treatment patient pancreatic cancer .</brief_summary>
	<brief_title>A Study Patients With Pancreatic Cancer</brief_title>
	<detailed_description>Phase 1 dose escalation dose 70 mg/m2 300 mg/m2 divide 6 cohort . Each patient assign single cohort intrapatient dose escalation . Patients receive gemcitabine day 1 , 8 , 15 follow LY2603618 day 2 , 9 , 16 28 day cycle . The phase 1 portion enroll approximately 26 patient total determine maximum tolerate dose carried phase 2 portion study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Diagnosed cancer metastatic and/or advance Phase 1 Diagnosed pancreatic cancer metastatic amenable surgery Must 18 year age Adequate hematological , liver , renal function ECOG status 02 Known hypersensitivity gemcitabine Pregnant lactating female refusal use medically approve contraceptive precaution Had prior treatment radiotherapy involve 25 % marrow produce area Have receive treatment last 30 day drug receive regulatory approval indication time study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>metastatic cancer</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>Pancreatic cancer</keyword>
</DOC>